In this episode of Talk Radioisotopes, host Scott Larrivee sits down with Sigal Kalmanson, CEO and Co-Founder of Starget Pharma, an early-stage company at the forefront of precision oncology. Starget is redefining the way radiopharmaceuticals are discovered and developed by merging AI technology with decades of expertise in peptide chemistry.
Sigal shares how Starget’s proprietary backbone cyclization technology and in silico AI models enable the rapid development of metabolically stable and highly specific radioligands for hard-to-treat cancers. She also explains the company’s unique platform approach, which optimizes isotopes, chelators, and ligands for targeted cancer therapies, all in accelerated timelines.
Listeners will learn about Starget’s innovative drug discovery pipeline, the company’s ambitions to enter clinical trials, and the broader implications for the future of radiopharmaceuticals. This episode is a must-listen for biotech professionals, oncology researchers, and investors tracking the next wave of AI-powered drug development.
——–
Time Stamps:
- *(01:48) The Science Behind Smart Targeted Radioligands
- *(04:02) AI and Peptide Radioligand Discovery
- *(06:31) Understanding Starget Pharma’s Product Pipeline
- *(11:26) Emerging Isotopes and Future Prospects
- *(13:10) Sigal’s Advice for the Early Stage Companies
- *(19:35) Sigal’s Magic Wand
——–
‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com.
——–
Links:
Follow Sigal
Visit Starget Pharma
Talkradioisotopes.com
——-
